CRT 2020: Anticoagulation vs antiplatelet therapy after TAVR — Dr Toby Rogers

Dr Toby Rogers (Medstar Washington Hospital Center, Washington, DC, US) discusses anticoagulation versus antiplatelet therapy after transcatheter aortic valve replacement in low risk patients.

This feasibility and hypothesis generating study assessed whether anticoagulation in a low risk population after TAVR for one month reduces subclinical leaflet thrombosis warfarin reduced this phenomenon without causing excessive bleeding. 


1. Why did you conduct this research? Do low risk patients provide unique challenges?
2. What was the study design, technology and drugs used and endpoints?
3. What did you find and what conclusions can be made?

Filmed on location at CRT 2020.

Interviewer: William Cadden
Videographer: Charlie McClanahan